genXone Competitors and Similar CompaniesClear all
genXone's competitors and similar companies include Nanobiosym, 20Med Therapeutics, Genturi and ReCode Therapeutics.
 Nanobiosym Nanobiosym (NBS) is a company that focuses on the commercialization of its proprietary technology platform, that can detect genetic fingerprints from biological organisms, providing people with diagnostic information about their health. |  20Med Therapeutics 20Med Therapeutics is a biotechnology company applying nanotechnology for the development of RNA therapeutics. |  ReCode Therapeutics ReCode Therapeutics is a company developing non-viral nanoparticles for delivery of diverse RNA- and protein-based therapeutics to targeted tissues, and tRNA NanoCorrectors. | |||
Founding Date | Founding Date 2016 | Founding Date 2004 | Founding Date 2011 | Founding Date 2018 | Founding Date 2015 |
Type | Type Private | Type Private | Type Private | Type Private | Type Private |
Tags | |||||
Locations | Locations Złotniki, PL HQ | Locations Cambridge, US HQ | Locations Leiden, NL HQ Enschede, NL | Locations Woburn, US HQ | Locations Menlo Park, US HQ |
Employees | Employees 156% decrease | Employees 9 | Employees 11 | Employees 433% increase | Employees 1062% decrease |
For sources of this data, please see the company profile
View Company Profiles
Nanobiosym
HQ
Cambridge, US
Employees
9
Nanobiosym (NBS) is a company that focuses on the commercialization of its proprietary technology platform, that can detect genetic fingerprints from biological organisms, providing people with diagnostic information about their health.
View company20Med Therapeutics
HQ
Leiden, NL
Employees
11
20Med Therapeutics is a biotechnology company applying nanotechnology for the development of RNA therapeutics.
View company
Genturi
HQ
Woburn, US
Employees
4↑ 33% increase
Genturi is a biotechnological company providing nanofluidic products.
View companyReCode Therapeutics
HQ
Menlo Park, US
Employees
106↓ 2% decrease
ReCode Therapeutics is a company developing non-viral nanoparticles for delivery of diverse RNA- and protein-based therapeutics to targeted tissues, and tRNA NanoCorrectors.
View company